Armstrong M, Daly A K, Cholerton S, Bateman D N, Idle J R
Department of Pharmacological Sciences, Medical School, Newcastle upon Tyne, UK.
Lancet. 1992 Apr 25;339(8800):1017-8. doi: 10.1016/0140-6736(92)90537-d.
The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls. The commonest mutant allele, CYP2D6B, was twice as frequent among patients as in controls, with an approximate relative risk ratio of 2.70 (95% confidence interval 1.14-6.41; p = 0.0063) for subjects homozygous or heterozygous for this allele.
